Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
agenT-797 in COVID-19 ARDS
NCT04582201Phase 1Completed
- Sponsor
- MiNK Therapeutics
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Allogeneic CAR-T, Lymphokine-Activated Killer Cells, Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of agenT-797 in acute respiratory distress syndrome (ARDS) (3 cohorts), sponsored by MiNK Therapeutics. Primary endpoints: Treatment-emergent Adverse Events at 6 months and Dose-limiting Toxicities at 6 months. Started Sep 2020; status: completed.
02
Drugs
agenT-797
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04582201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582201.